Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

Avner Thaler*, Shani Shenhar-Tsarfaty, Yanay Shaked, Tanya Gurevich, Nurit Omer, Anat Bar-Shira, Mali Gana-Weisz, Orly Goldstein, Meir Kestenbaum, Jesse M. Cedarbaum, Avi Orr-Urtreger, Nir Giladi, Anat Mirelman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk, we collected, laboratory test results, blood pressure, demographic, cognitive, motor, olfactory and affective information enabling the assessment of each component of MS and the construction of the MDS prodromal probability score. The number of metabolic components and their levels were compared between participants who were separated based on disease state and genetic status. One hundred and four idiopathic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated in this study. PD groups and non manifesting carriers (NMC) did not differ in the number of metabolic components (p = 0.101, p = 0.685, respectively). LRRK2-PD had higher levels of triglycerides (p = 0.015) and higher rates of prediabetes (p = 0.004), while LRRK2-NMC had higher triglyceride levels (p = 0.014). NMC with probability rates for prodromal PD above 50% had higher frequencies of hypertriglyceridemia and prediabetes (p < 0.005, p = 0.023 respectively). While elevated triglycerides and prediabetes were more frequent among LRRK2 carriers, MS does not seem to influence GBA and LRRK2-PD phenotype.

Original languageEnglish
Article number9329
JournalScientific Reports
Volume10
Issue number1
DOIs
StatePublished - 1 Dec 2020

Funding

FundersFunder number
Israeli Innovation Authority
LTI
Sagol School of Neuroscience and Parkinson’s Foundation
Silverstein Foundation16503
Michael J. Fox Foundation for Parkinson's Research
National Parkinson Foundation
Pfizer
Biogen
Teva Pharmaceutical Industries
Seventh Framework Programme
Sanofi Genzyme
Israel Science Foundation

    Fingerprint

    Dive into the research topics of 'Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease'. Together they form a unique fingerprint.

    Cite this